Drug Trial Radar · NCT06747936
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
129
Actual
Start
Feb 3, 2025
Primary completion
May 30, 2025
Study completion May 30, 2025
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia
Conditions
- Primary Hypercholesterolemia
Interventions
AD-2281Drug
PO, Once daily, 8weeks
AD-2282Drug
PO, Once daily, 8weeks
Placebo of AD-2282Drug
PO, Once daily, 8weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change rate of LDL-CTime frame: from baseline at 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital
Seoul, Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.